228 325

Cited 12 times in

Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients.

Authors
 Seung Jin Han  ;  Kyu Yeon Hur  ;  Yu Seun Kim  ;  Eun Seok Kang  ;  Soon Il Kim  ;  Myoung Soo Kim  ;  Jung Young Kwak  ;  Dae Jung Kim  ;  Sung Hee Choi  ;  Bong Soo Cha  ;  Hyun Chul Lee 
Citation
 NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol.25(3) : 976-984, 2010 
Journal Title
 NEPHROLOGY DIALYSIS TRANSPLANTATION 
ISSN
 0931-0509 
Issue Date
2010
MeSH
Adiponectin/blood ; Adult ; Atherosclerosis/drug therapy* ; Atherosclerosis/physiopathology ; Carotid Arteries/diagnostic imaging ; Disease Progression ; Female ; Glucose Intolerance/drug therapy* ; Glucose Intolerance/physiopathology ; Humans ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use* ; Insulin Resistance/physiology* ; Kidney Transplantation/physiology* ; Lipids/blood ; Male ; Middle Aged ; Thiazolidinediones/pharmacology ; Thiazolidinediones/therapeutic use* ; Transplantation, Homologous ; Ultrasonography
Keywords
carotid intima–media thickness ; insulin resistance ; pioglitazone ; renal allograft
Abstract
BACKGROUND: The aim of this study was to evaluate the effect of pioglitazone treatment on the progression of subclinical atherosclerosis and insulin resistance in renal allograft recipients with no preoperative history of diabetes. METHODS: Eighty-three patients without diabetes were randomly assigned to either the pioglitazone group or the control group. Carotid intima-media thickness (IMT), serum adiponectin level and lipid profile were assessed before transplantation and at 12 months after transplantation. Insulin secretory function and insulin resistance were evaluated by the oral glucose tolerance test. RESULTS: The pioglitazone group showed a significant reduction in the mean and maximum carotid IMT compared with the control group after 12 months (mean carotid IMT, 0.05 +/- 0.04 vs -0.03 +/- 0.07 mm, P < 0.001; maximum carotid IMT, 0.08 +/- 0.05 vs -0.05 +/- 0.09 mm, P < 0.001). Pioglitazone increased the adiponectin level, and the change in adiponectin was negatively correlated with carotid IMT changes. Pioglitazone treatment increased the insulin sensitivity index compared with the control group (-0.8 +/- 3.1x10(-)(2) vs +1.1 +/- 3.7x10(-)(2), P = 0.036). CONCLUSIONS: These results suggest that pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance in renal allograft recipients without a history of diabetes. Trial Registration. Clinicaltrials.gov Identifier: NCT00598013
Files in This Item:
T201000550.pdf Download
DOI
10.1093/ndt/gfp567
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Kim, Myoung Soo(김명수) ORCID logo https://orcid.org/0000-0002-8975-8381
Kim, Soon Il(김순일) ORCID logo https://orcid.org/0000-0002-0783-7538
Kim, Yu Seun(김유선) ORCID logo https://orcid.org/0000-0002-5105-1567
Lee, Hyun Chul(이현철)
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
Han, Seung Jin(한승진)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/100708
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse